Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation
STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation